WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H326682
CAS#: 138470-70-9 (HCl)
Description: Mozavaptan, also known as OPC 31260, is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
Hodoodo Cat#: H326682
Name: Mozavaptan HCl
CAS#: 138470-70-9 (HCl)
Chemical Formula: C27H30ClN3O2
Exact Mass: 0.00
Molecular Weight: 464.010
Elemental Analysis: C, 69.89; H, 6.52; Cl, 7.64; N, 9.06; O, 6.90
Related CAS #: 138470-70-9 (HCl) 137975-06-5 (free base)
Synonym: OPC-31260; OPC 31260; OPC31260; Mozavaptan HCl.
IUPAC/Chemical Name: N-(4-(5-(dimethylamino)-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)phenyl)-2-methylbenzamide hydrochloride
InChi Key: MOROBKPIULFQDC-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H29N3O2.ClH/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30;/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31);1H
SMILES Code: CC1=C(C(NC2=CC=C(C(N3C(C=CC=C4)=C4C(N(C)C)CCC3)=O)C=C2)=O)C=CC=C1.Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent vasopressin V2 receptor antagonist with an IC50 of 14 nM. |
| In vitro activity: | This paper describes the ability of OPC-31260 to inhibit AVP receptor binding in rat liver and kidney plasma membranes. Both AVP and OPC-31260 displaced [3H]-AVP binding to rat liver (V1 receptor) and kidney (V2 receptor) plasma membranes (Figure 2). The IC50 value of OPC-31260 was 1.4 + 0.2 x 10- 8M for V2 receptors and 1.2 + 0.2 x 10-6 M for V1 receptors (n = 3); the corresponding IC50 values for AVP were 4.0 + 0.4 x 109Mat V2 and 2.3 + 0.5 x 10-9M at V1 receptors. OPC-31260 is therefore two orders of magnitude. Scatchard plots of [3H]-AVP saturation binding in the absence and presence of OPC-31260 were determined. Kd and Bmax values for [3H]-AVP in rat liver were 1.10+ 0.14 x 10-9M and 1.96 +0.30 x 10-2molmgprotein respectively; in rat kidney the corresponding values were 1.38 + 0.08 x 10-9M, 0.40 + 0.03 x 10-12molmg'I protein. The Kd of [3H]-AVP was reduced significantly in both rat liver and kidney in the presence of OPC-3 1260 although Bmax values did not change in either tissue (Table 1). The results indicate that OPC-31260 inhibits [3H]-AVP more selective for V2 receptors than for V1 receptors. In conclusion, the present studies confirm that OPC-31260 inhibits AVP binding to V1 and V2 receptors in a competitive manner and that it is about 100 times more selective for V2 receptors. It is expected that OPC-31260 will be a useful probe for studying the physiological and pathophysiological role of AVP and treatment of diseases associated with water imbalanced states. Reference: Br J Pharmacol. 1992 Apr;105(4):787-91. https://pubmed.ncbi.nlm.nih.gov/1387020/ |
| In vivo activity: | The present study was undertaken to determine whether the non-peptide V2 antidiuretic hormone (ADH) antagonist 5-dimethylamino1[4-(2- methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine (OPC-31260) normalized hyponatremia in rats with an experimental syndrome of inappropriate secretion of ADH (SIADH). Rats were administered V2 agonist 1-deamino-8-D-arginine vasopressin (dDAVP) subcutaneously at a rate of 5 ng/hr using an osmotic minipump and a 40 ml/day liquid diet. Serum sodium levels (SNa) and serum osmolality (SOsm) markedly decreased to 119 mEq/liter and 249 mOsm/kg H2O, respectively, 48 hours after the start of dDAVP administration. Hyponatremia persisted in a similar magnitude during the observation period of 14 days. On days 7 to 13 OPC-31260, administered 5 mg/kg per day orally, promptly raised SNa and SOsm to 134 mEq/liter and 282 mOsm/kg H2O in half a day, respectively, followed by the normalization of SNa and SOsm during the rest of the observation period. The cease of administration of OPC-31260 again decreased SNa and SOsm in rats receiving dDAVP. In contrast, SNa and SOsm were within the normal values in rats receiving 0.15 M NaCl, a vehicle for dDAVP, in the presence or absence of OPC-31260. The administration of OPC-31260 promptly caused marked water diuresis on day 7 in the hyponatremic rats receiving dDAVP, namely 5 mg/kg OPC-31260 markedly increased urinary volume and decreased UOsm. These results indicate that there is dilutional hyponatremia in rats receiving dDAVP and 40 ml/day liquid diets, and that OPC-31260 is an effective therapeutic for hyponatremia associated with dDAVP-induced SIADH. Reference: Kidney Int. 1993 Jul;44(1):19-23. https://pubmed.ncbi.nlm.nih.gov/8355461/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| Soluble in DMSO | 30.0 | 64.70 |
The following data is based on the product molecular weight 464.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Fujisawa G, Ishikawa S, Tsuboi Y, Okada K, Saito T. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int. 1993 Jul;44(1):19-23. doi: 10.1038/ki.1993.207. PMID: 8355461. 2. Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005 Apr;16(4):846-51. doi: 10.1681/ASN.2004121090. Epub 2005 Feb 23. PMID: 15728778 3. Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992 Apr;105(4):787-91. doi: 10.1111/j.1476-5381.1992.tb09058.x. PMID: 1387020; PMCID: PMC1908728. |
| In vitro protocol: | 1. Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992 Apr;105(4):787-91. doi: 10.1111/j.1476-5381.1992.tb09058.x. PMID: 1387020; PMCID: PMC1908728. |
| In vivo protocol: | 1. Fujisawa G, Ishikawa S, Tsuboi Y, Okada K, Saito T. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int. 1993 Jul;44(1):19-23. doi: 10.1038/ki.1993.207. PMID: 8355461. 2. Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005 Apr;16(4):846-51. doi: 10.1681/ASN.2004121090. Epub 2005 Feb 23. PMID: 15728778 |
1: Yamazaki T, Fukata A, Muraki Y. Imidafenacin exerts the antidiuretic effect by enhancing vasopressin-related responses in orally water-loaded rats. Eur J Pharmacol. 2016 Nov 15;791:72-77. doi: 10.1016/j.ejphar.2016.08.021. PubMed PMID: 27568834.
2: Sharif SA, Calder ED, Delolo FG, Sutherland A. Synthesis of 5-Amino-2,5-dihydro-1H-benzo[b]azepines Using a One-Pot Multibond Forming Process. J Org Chem. 2016 Aug 5;81(15):6697-706. doi: 10.1021/acs.joc.6b01357. PubMed PMID: 27414232.
3: Tabata K, Nishimura Y, Takeda T, Kurita M, Uchiyama T, Suzuki T. Sesquiterpene lactones derived from Saussurea lappa induce apoptosis and inhibit invasion and migration in neuroblastoma cells. J Pharmacol Sci. 2015 Apr;127(4):397-403. doi: 10.1016/j.jphs.2015.01.002. PubMed PMID: 25953266.
4: Verbalis JG, Grossman A, Höybye C, Runkle I. Review and analysis of differing regulatory indications and expert panel guidelines for the treatment of hyponatremia. Curr Med Res Opin. 2014 Jul;30(7):1201-7. doi: 10.1185/03007995.2014.920314. Review. PubMed PMID: 24809970.
5: Izumi Y, Miura K, Iwao H. Therapeutic potential of vasopressin-receptor antagonists in heart failure. J Pharmacol Sci. 2014;124(1):1-6. Review. PubMed PMID: 24401675.
6: Roix J, Saha S. TNF-α blockade is ineffective in animal models of established polycystic kidney disease. BMC Nephrol. 2013 Oct 25;14:233. doi: 10.1186/1471-2369-14-233. PubMed PMID: 24160989; PubMed Central PMCID: PMC4231369.
7: Tamura T, Takeuchi K. Small cell gall bladder carcinoma complicated by syndrome of inappropriate secretion of antidiuretic hormone (SIADH) treated with mozavaptan. BMJ Case Rep. 2013 Jun 11;2013. pii: bcr2013010039. doi: 10.1136/bcr-2013-010039. PubMed PMID: 23761568; PubMed Central PMCID: PMC3702909.
8: Dabrowska MD, Krysiak R, Okopień B. [Hyponatremic hypervolemia in heart failure--the hot spot for vasopressin receptor antagonists?]. Wiad Lek. 2012;65(1):19-30. Review. Polish. PubMed PMID: 22827112.
9: Takahashi K, Makita N, Manaka K, Hisano M, Akioka Y, Miura K, Takubo N, Iida A, Ueda N, Hashimoto M, Fujita T, Igarashi T, Sekine T, Iiri T. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists. J Biol Chem. 2012 Jan 13;287(3):2099-106. doi: 10.1074/jbc.M111.268797. PubMed PMID: 22144672; PubMed Central PMCID: PMC3265889.
10: Devuyst O, Wang X, Serra A. Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back. Nephrol Dial Transplant. 2011 Aug;26(8):2423-5. doi: 10.1093/ndt/gfr380. PubMed PMID: 21803730.
11: Meijer E, Gansevoort RT, de Jong PE, van der Wal AM, Leonhard WN, de Krey SR, van den Born J, Mulder GM, van Goor H, Struck J, de Heer E, Peters DJ. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant. 2011 Aug;26(8):2445-53. doi: 10.1093/ndt/gfr069. PubMed PMID: 21393612.
12: Villabona C. [Vasopressin receptor antagonists: the vaptans]. Endocrinol Nutr. 2010 May;57 Suppl 2:41-52. doi: 10.1016/S1575-0922(10)70021-8. Review. Spanish. PubMed PMID: 21130961.
13: Ectopic ADH Syndrome Therapeutic Research Group., Yamaguchi K, Shijubo N, Kodama T, Mori K, Sugiura T, Kuriyama T, Kawahara M, Shinkai T, Iguchi H, Sakurai M. Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome. Jpn J Clin Oncol. 2011 Jan;41(1):148-52. doi: 10.1093/jjco/hyq170. PubMed PMID: 21087977.
14: Takada M, Fujimaki-Aoba K, Hokari S. Vasotocin- and mesotocin-induced increases in short-circuit current across tree frog skin. J Comp Physiol B. 2011 Feb;181(2):239-48. doi: 10.1007/s00360-010-0523-5. PubMed PMID: 20981549.
15: Nishimura M, Kakigi A, Takeda T, Okada T, Doi K. Bumetanide-induced enlargement of the rat intrastrial space and effects of a vasopressin type 2 antagonist. ORL J Otorhinolaryngol Relat Spec. 2010;71 Suppl 1:10-5. doi: 10.1159/000265114. PubMed PMID: 20185944.
16: Takeda T, Takeda S, Kakigi A, Okada T, Nishioka R, Taguchi D, Nishimura M, Nakatani H. Hormonal aspects of Ménière's disease on the basis of clinical and experimental studies. ORL J Otorhinolaryngol Relat Spec. 2010;71 Suppl 1:1-9. doi: 10.1159/000265113. Review. PubMed PMID: 20185943.
17: Takada M, Fujimaki-Aoba K, Hokari S. Effects of arginine vasotocin and mesotocin on the activation and development of amiloride-blockable short-circuit current across larval, adult, and cultured larval bullfrog skins. J Comp Physiol B. 2010 Mar;180(3):393-402. doi: 10.1007/s00360-009-0424-7. PubMed PMID: 19949800.
18: Yeung PK, Lo AC, Leung JW, Chung SS, Chung SK. Targeted overexpression of endothelin-1 in astrocytes leads to more severe cytotoxic brain edema and higher mortality. J Cereb Blood Flow Metab. 2009 Dec;29(12):1891-902. doi: 10.1038/jcbfm.2009.175. PubMed PMID: 19707218.
19: Shibata H. [Treatment for the electrolytic disorders in cancer patients]. Gan To Kagaku Ryoho. 2008 Dec;35(13):2330-3. Japanese. PubMed PMID: 19098400.
20: Bie P, Mølstrøm S, Wamberg S. Normotensive sodium loading in conscious dogs: regulation of renin secretion during beta-receptor blockade. Am J Physiol Regul Integr Comp Physiol. 2009 Feb;296(2):R428-35. doi: 10.1152/ajpregu.90753.2008. PubMed PMID: 19073902.
